PDCD1 and neoplasm: Five years ago a case report described a patient with R/R B-ALL who experienced an increase in PD-1 and PD-L1 positivity after treatment with blinatumomab, in vitro experiments showed the ability of T cells inducing tumor cell lysis was weakened with a lower level of interferon γ (IFN-γ) in this patient [111].